

Index

Note: page numbers in bold indicate tables or figures

- abuse, correlated with suicidal behaviour 272–4
- adolescent challenges 65–8
- adolescent depression
  - bipolar disorders 367–8
  - clinical depression 148–9
  - compared with childhood depression **294**
  - bipolar disorders 367–8
  - gender effects 148–9
  - major depressive disorder 123
  - contextual psychotherapy (CP) 338
  - Coping with Depression (CWD) course 329–30, 336, 339
  - interpersonal therapy (IPT-A) 337
  - life events 224–5
  - Virginia Twin Study of Adolescent Behavioral Development 162
  - see also* pubertal status
- adrenal, hypothalamic–pituitary–adrenal axis 87–90, 242–9
- adrenarche 86
- adrenocorticotrophic hormone (ACTH) 242–3
- adult, *see also* family; life event; parental
- adult depression
  - classification of depressive disorders 126–8, 292
  - neurotic vs. psychotic 119
  - offspring of affectively ill parents 181–90
  - vs. other outcomes, comorbid linkages 179–80
  - relatives of juvenile probands
  - affective disorders 190–5
  - bipolar disorders **193**
  - unipolar disorders **193**
- adult psychiatry
  - contribution to concept of childhood depression 119–20
  - life events studies 223–4
- adverse experiences *see* life events
- affective disorders *see* depressive disorders
- age effects
  - epidemiology of depression 148–9
  - scale score studies 149–50
- aggression, as coping response 56
- alcohol use, and suicidal behaviour 281–3
- algorithms, diagnosis 135–6
- American Indian Study **145**
- amitriptyline, dosage and plasma level monitoring **303**
- amphetamine 95
- anaclitic depression 12
- androgens, in development 86, 365
- anorexia nervosa
  - prepubertal endocrine secretion patterns 87
  - TSH blunting 241
- antidepressant treatment
  - historical aspects **295**
  - see also* pharmacology; tricyclic antidepressants
- anxiety disorders
  - comorbidity 81–2, 129, 131–3
  - suicidal behaviour 281–2
- arecoline 253
- asylums, historical aspects 10–11
- attachment, and mechanisms for development of depression in offspring 48
- attention deficit hyperactivity disorder (ADHD) and bipolar disorders 147
  - epiphenomenal comorbidity 158
- attributional style 57
- atypical depression, weight changes 100
- automatisms 24–5
- autonomy, development, and parental effects 50–2
- Beck Depression Inventory 332, 354
- behaviouristic source (of emotional intelligence) 26
- behaviours
  - coping behaviours 55–7
  - help-seeking behaviours, and suicidal ideation 275
  - standards and perceptions 32–3
- bereavement *see* loss
- biological vulnerability 361
- bipolar disorders
  - adolescent vs. child 367–8
  - adult relatives of juvenile probands 190–5, **193**

Cambridge University Press

0521794269 - The Depressed Child and Adolescent, Second Edition

Edited by Ian M. Goodyer

Index

[More information](#)**383 Index**

- Amish study 196
- course 367–8
- epidemiology 146–7
  - and ADHD 147
  - lifetime prevalence 147
- family aggregation 100, 187
- NIMH Initiative Study 189
- treatment regimes 311–13
- and X-linked inheritance 197
- British birth cohort study 355
- carbamazepine, bipolar disorders 313
- Caring for Children in the Community Study (CCCS) 146, 150
- Carolina Longitudinal Study 151
- catecholamine systems, maturation 95
- Child Behavior Checklist 127, 133
- childhood depression *see* adolescent depression, compared with childhood depression
- cholinergic system 94–5
  - challenges 253
- chronic diseases/disorders, childhood-onset 343
- classification of depressive disorders 126–8, 292
- clinical depression *see* dysthymic disorder; major depressive disorder
- clinical phenomenology 119–37
- clomipramine
  - dosage and plasma level monitoring **303**
  - in OCD 306
- clonidine 95
  - challenge 237–8
- clorgyline 298
- cluster analysis 126–7
- cognitive behaviour therapy (CBT) 329–34, 343
  - modified for adolescents 337
- cognitive styles 57–9
  - differential activation hypothesis 58
  - psychology of suicidal behaviour 276
- cognitive vulnerability 359–61
- comorbidity 128–33
  - anxiety disorders 129, 131–3
  - suicidal behaviour 281–4
  - childhood-onset diseases 343
- conduct/oppositional defiant disorder (CD/ODD) 155–8, 160–2
- developmental linkages, adult depression vs. other outcomes 179–80
- dysthymic disorder 158–9, 327–8
- epiphenomenal comorbidity 158
- externalizing disorders 133
- homotypic vs. heterotypic 155–6
  - heterotypic, as marker of severity 159–60
  - homotypic, major depression and dysthymia 158–9
- nondepressive psychopathology, mechanisms
  - involved in recurrence/continuity of depressive disorders 363
- other mental disorders 81–2
- pharmacology 293–4
- school refusal disorder 129
- strengths of associations **156**
- concomitants of depression 97–9
- conduct/oppositional defiant disorder (CD/ODD)
  - comorbidity 155–8, 160–2
  - concurrent vs. successive comorbidity 156–7
  - meaning 157
- contextual psychotherapy (CP) 338
- continuity of depressive disorders *see* recurrence/continuity
- coping behaviours
  - gender effects 55–6
  - and regulation of emotions 55–7
  - response as aggression 56
- Coping with Depression (CWD) course 329–30, 336, 339
- corticotrophin-releasing hormone (CRH) 242–3
  - stimulation test 247–9
- cortisol 242–9
  - basal secretion 243–5
  - dexamethasone suppression test 89, 245–7, 361
  - HPA axis stimulation tests 245–9
  - levels, and depression risk 221–2, 361
  - stimulated secretion 87–8, 90
- cytochrome P450 isoenzymes, inhibition by SSRIs **311**
- definitions
  - depressive disorder 125
  - disorder 125
  - suicidal ideation 268
  - suicide 268
  - syndrome(s) 124–5
  - types of loss 211
- dehydroepiandrosterone (DHEA) levels 88
  - and cortisol 243, 244
  - and depression risk 221–2, 245
- depressed mood, rates 125
- depressive disorders *see* dysthymic disorder; major depressive disorder
- desipramine 237, 251, 252, 300
  - dosage and plasma level monitoring **303**
  - side-effects 304–6
- desmethylimipramine 95
- desmethylsertraline **311**
- developmental precursors of depression 46–68
  - adolescent challenges 65–8
  - attachment 48
  - family studies 47–52
  - individual characteristics 52–63
  - model of depression 67–8
  - peer relationships and social competence 63–5
- dexamethasone suppression test 89, 245–7, 361
- diabetes mellitus, and MDD 338
- diagnosis
  - age and gender, unipolar disorders 148
  - algorithms 135–6
  - clinical depression, vs. depressed affect 80–1, 117
  - clinically diagnosed samples, psychotherapy 329–34
  - more and less severe forms 102

Cambridge University Press

0521794269 - The Depressed Child and Adolescent, Second Edition

Edited by Ian M. Goodyer

Index

[More information](#)**384 Index**

- diagnosis (*cont.*)  
 and pubertal status 92, 117, 151–3  
 Research Diagnostic Criteria (RDC) 182, 190–3  
 schemas 133–5  
 and stage of puberty 92  
 trend to uniformity across age groups 14
- diagnostic criteria  
*DSM-IV* 80–1, 120–1  
 dysthymic disorder 121–3, 129–31  
*ICD-10* 121–2  
 major depressive disorder 120, 122–3, 129–31
- Diagnostic Interview for Children and Adolescents (DICA) 182, 184–5
- Diagnostic Interview Schedule for Children (DISC) 182
- differential activation hypothesis 58
- discontinuity and recovery 364–7
- disorder, defined 125
- diurnal rhythms 92–4
- dopamine D<sub>2</sub> receptors, thyroid hormone 238
- double hit hypothesis 207–8
- drug use *see* substance use
- DSM-IV*, diagnostic criteria 80–1, 120–1
- Dunedin Longitudinal Study (DMDHS) **144**, 149, 355
- duration of episodes of depression 326  
*see also* recurrence/continuity
- dysphoria, and depressive affect 124–5
- dysthymic disorder  
 association between parent and offspring 185–7  
 characteristics 325–8  
 comorbidity 158–9, 327–8  
 diagnostic criteria 121–3, 129–31  
 duration 326  
 onset 326  
 recovery rate 326  
 risk posed 327  
 superimposition of MDD 326  
 treatment regimes 325–45  
 outcome studies 328–37  
*see also* major depressive disorder
- electroconvulsive therapy (ECT), thyroid secretion 239
- emotional intelligence 24–40  
 automatisms 24–5  
 early concepts 27–8  
 historical aspects 27  
 regulation of emotions 34–8, 55–7  
 social emotions 31–4  
 theory of 29–31
- emotional support, loss/absence 217
- emotionally biased thinking 38–9
- endocrine dysregulation 85–92  
*see also* hypothalamic–pituitary axes;  
 neuroendocrine studies
- endorphins 90
- environmental risk factors for depression 163–4, 188–90
- Epidemiological Catchment Area (ECA) study 148
- epidemiology 143–5  
 comorbidity 155–62  
 environmental risk factors 163–4, 188–90  
 ethnicity 154  
 gender and age 148–9  
 scale score studies 149–50  
 prevalence of depressive disorders 80–4, 143–50, 179  
 bipolar disorders 146–7  
 puberty 151–4  
 rates from community studies **144–5**  
 unipolar disorders 143–6, 162–3  
 suicide 268–70
- exploratory factor analysis 126
- externalizing disorders, comorbidity 133
- false belief paradigm 30
- family history-RDC (FH-RDC) 182, 190–3
- family and rearing environment 47–52, 179–98  
 aggregation 195–7  
 bipolar depression 100, 187  
 continuity of depression across generations 99–102  
 development of autonomy 50–2  
 family/genetic vulnerability 361–2  
 interaction with depressed offspring 48–50, 328  
 risk transmission 181, 188–90  
 status of offspring of depressed parents 180–90  
 nonaffective conditions 187–8  
 specific risk factors 163–4, 188–90  
 transmission of risk 181
- fluoxetine  
 dosage **310**  
 effectiveness 96–7, 309  
 half-life **311**  
 and serotonin 307–8
- folie circulaire* 7, 8
- fresh start events 223
- friendship 224  
*see also* peer relationships
- gender effects  
 clinical depression 56, 81  
 children vs. adolescents 148–9  
 coping 55–6  
 developmental pathways 66–7  
 personality features 62–3  
 scale score studies 149–50  
 social and nonsocial factors in life events 219–20  
 thyroid hormone secretion 239  
 unipolar disorders 148
- gender socialization 67
- genetic epidemiology of unipolar disorders 162–3
- genetic influences, life events 210–11
- genetic/environmental factors  
 family studies 47–52, 179–98  
*see also* family and rearing environment
- gonadarche 86
- Great Smoky Mountains Study (GSMS) **145**, 146, **150**, 153

385 Index

- growth hormone 235–8
  - basal secretion 236–7
  - hypothalamic–pituitary–somatotrophic axis 90, 95, 235
  - and somatostatin 238
  - stimulated secretion 237–8
- growth hormone-binding protein 236
- guilt 31
- help-seeking behaviours, and suicidal ideation 275
- historical aspects 1–18
  - antidepressant treatment **295**
  - conceptions of childhood 3–4
  - nineteenth century 5–7
  - pre nineteenth century 4–5
  - theories of causation 9–10
  - twentieth century 11–17, 292
- 5-hydroxy-L-tryptophan (L-5HTP) 253
- hypochondriasis, historical aspects 6–7
- hypoglycaemia, insulin-induced 237
- hypomania 11
- hypothalamic–endocrine dysregulation 85–7
- hypothalamic–pituitary (HP) axes
  - HP–adrenal axis 87–90, 242–9
  - HP–gonadal axis 91–2
  - HP–growth hormone axis 90, 95, 235–8
  - HP–thyroid axis 90–1, 238
- ICD-10*, diagnostic criteria 121–2
- imipramine 253, 294–5, 299
  - dosage and plasma level monitoring **303**
  - electrocardiography 316–17
  - side-effects 304–6
- imitation, impulsivity, psychology of suicidal behaviour 277–9
- individual characteristics 52–63
- insanity, historical aspects 9
- interpersonal therapy (IPT) 332
  - adolescent version IPT-A 337
- interviews
  - Diagnostic Interview for Children and Adolescents (DICA) 182, 184–5
  - Diagnostic Interview Schedule for Children (DISC) 182
  - Standard Psychiatric Interview 134
- Kiddie-SADS *see* Schedule for Affective Disorders and Schizophrenia in School-Age Children (K-SADS)
- kindling 97
- learned helplessness 209–10
- life events 204–27
  - adults 223–4
  - children/adolescents 224–5
  - clinical implications 225–6
  - and emotional disorders 205
  - environmental causes of depression 207–10
  - evaluation 204–7
  - genetic influences 210–11
  - lock and key process 213–15
  - longitudinal studies 217–19
  - loss and depression 216–17
  - precedence of experience to disorder 206–7
  - social and nonsocial factors
    - gender differences 219–20
    - major depression 219–22
  - specificity 226–7
  - and stress levels 99–100
  - undesirable, classification 211–12
- lithium
  - characteristics **314**
  - dosage in bipolar disorders 313
  - indications **314**
  - side-effects **315**
- lock and key process, life events 213–15
- locus ceruleus–noradrenaline system 95
- longitudinal studies
  - Carolina Longitudinal Study 151
  - Dunedin Longitudinal Study (DMDHS) **144**, 149, 355
  - life events 217–19
  - melatonin 251–2
  - New York Longitudinal Study **144**, 355
- loss
  - and depression 216–17
  - types and definition 211
- luteinizing hormone, and melatonin 250
- lypomania 5
- major depressive disorder
  - characteristics 325–8
  - children vs. adolescents 123
  - clinical features, child vs. adolescent **294**
  - comorbidity 158–9
  - vs. depressed affect 80–1, 117
  - dexamethasone suppression test 89, 245–7
  - diagnostic criteria 120, 122–3, 129–31
  - duration 326
  - gender differences 56, 81
  - prevalence 80–4
  - recurrence risk 353–4
  - social and nonsocial life events factors 219–22
  - treatment regimes 292–317
    - outcome studies 328–37
    - see also* dysthymic disorders
- mania and manic-depressive insanity, historical aspects 8
- mania *see* bipolar disorders
- maprotiline, dosage and plasma level monitoring **303**
- markers of depression 84–97
- masked depression 14, 123–4
- maternal dominance, development of autonomy 50–2
- media influences, and suicide 279
- melancholia 5–6
  - theories of causation 9–11
- melatonin 249–52
  - longitudinal studies 251–2

Cambridge University Press

0521794269 - The Depressed Child and Adolescent, Second Edition

Edited by Ian M. Goodyer

Index

[More information](#)**386 Index**

- melcortisol, basal secretion 250–1
- menarche 86, 91, 274
- 3-methoxy-5-hydroxyphenylglycol (MHPG) 254
- moclobemide 297, **298**
- monoamine oxidase, activity 253
- monoamine oxidase inhibitors (MAOIs)
  - action **308**
  - adverse effects **297**
  - classification **297**
  - contraindications 299
  - historical aspects 295, 296
  - psychopharmacology 296–9
  - reversible type A (RIMAs) 295
- N-acetyl transferase (NAT) 249
- National Comorbidity Survey (NCS) 149
- natural history of mood disorders 353–71
- nefazodone 311
- negative experiences 207–9
- neuroendocrine studies 233–54
  - dysregulation of neurotransmitter systems 94–7
  - dysregulation of sleep patterns 92–4
  - multiple hormone response 252–3
  - see also* named hormones
- neurotransmitter systems 94–7
  - principles **295**
- New York Longitudinal Study **144**, 355
- Newcastle Depression Inventory 134–6
- nonaffective disorders, offspring of depressed
  - parents 187–8
- nondirective supportive therapy (NST) 331–2
- noradrenaline
  - and melatonin 250
  - peripheral markers 253–4
- noradrenergic and specific serotonergic
  - antidepressant (NASSA) 295
- noradrenergic system 94–5
- nortriptyline 299
- oestrogens
  - in development 365
  - markers in depression 91–2
- Ontario Child Health Study **144**, 146
- Oregon Adolescent Depression project **145**, 147, 152, 355
- P4502D6 isoenzyme, genetics 304
- parental depression
  - mechanisms for depression in offspring 47–8
  - offspring of affectively ill parents 181–90
  - and role in child treatment regimes 341–2
  - specific risk factors 188–90
  - status of offspring of depressed parents 163–4, 188–90
  - see also* family
- parental overprotection 51–2
- parental role, involvement in treatment regimes
  - 341–2
- paroxetine
  - dosage **310**
  - effectiveness 309
  - half-life **311**
- peer relationships
  - friendship impairment 224, 356
  - and social competence 63–5
- peptidergic neurotransmitters 239
- personality 60–3
- pharmacotherapy 292–317
  - historical aspects **295**
  - indications 314–17
  - recommendations 316–17
- phenelzine 297, 298
- phobias, comorbidity 81–2
- physical development 66–7
- physiological processes 79–103
  - concomitants of depression 97–9
  - continuity across developmental stages 83
  - and drug therapy 96
  - endocrine dysregulation 85–92
  - genetic/environmental factors 99–102
  - markers of depression 84–97
  - rates of depression 80–4
- pineal gland, melatonin 249–52
- Pittsburgh Pediatric Study **144**
- platelets, monoamine oxidase activity 253
- preexisting features linked with depression 61–2
- predictors of depression 97–9
- prevalence of depression 80–4
- Primary and Secondary Control Enhancement Training (PASCET) 336
- principal component analysis (PCA) 126, 126–7, 134–5, 343
- prolactin, response to 5-hydroxy-L-tryptophan (L-5HTP) 253
- Prozac *see* fluoxetine
- psychiatric illness, adult relatives of probands 190–5
- psychopathology, family aggregation 100–2
- psychopharmacology 292–317
- psychosocial treatments 337–40
- psychotherapy
  - clinically diagnosed samples 329–34
  - special needs 343
- pubertal status
  - and diagnosis of depression 92, 117, 151–3
  - discontinuity and recovery from depression 364–7
  - hormonal studies, and psychopathology 153–5
  - hypothalamic–endocrine regulation 86–7
  - morphological stage 151–3
  - see also* adolescent; menarche
- recovery 364–7
- recurrence/continuity of depressive disorders
  - 355–64
  - across developmental stages 83
  - across generations 99–102
  - chronicity 366–7
  - continuation and maintenance treatments 369–71
  - discontinuity and recovery 364–7

Cambridge University Press

0521794269 - The Depressed Child and Adolescent, Second Edition

Edited by Ian M. Goodyer

Index

[More information](#)**387 Index**

- major depressive disorder 353–4
- management implications 369–71
- mechanisms involved 358–64
  - biological vulnerability 361
  - cognitive vulnerability 359–61
  - comorbidity with nondepressive psychopathology 363
- direct persistence of initial depression 358–9
- family environment 362
- family/genetic vulnerability 361–2
- scarring/sensitization 359, 371
- short- and long-term 353–5
- and social impairment 355–6
- subsequent social impairment 355–6
- and suicidal behaviour 356–8
- see also* recurrence risk
- relaxation training (RT) 331
- reproduction, hypothalamic–pituitary–gonadal axis 91–2
- Research Diagnostic Criteria (RDC) 182
  - family history-RDC (FH-RDC) 182, 190–3
- reserpine, action 295
- risk factors
  - combinations predicting continuity of depression 363–4
  - cortisol levels 221–2, 361
  - dehydroepiandrosterone (DHEA) levels 221–2, 245
  - dysthymic disorder 327
  - environmental risk factors 163–4, 188–90
  - family and rearing environment 163–4, 181, 188–90
  - nondiagnosed depressed/at-risk samples, treatment regimes 334–7
  - parental depression 188–90
  - sex hormone levels 221–2
  - suicidal behaviour 357–8
  - see also* suicidal behaviour
- rumination 55–6
- SADS-Lifetime 184
- scarring/sensitization
  - recurrence of depression 359
  - and recurrence/continuity 359, 371
- Schedule for Affective Disorders and Schizophrenia in School-Age Children (K-SADS) 127, 134–5, 182–3, 191–2
  - principal component analysis (PCA) 126–7, 134–5
- scopolamine 253
- seasonal affective disorder (SAD) 368–9
- self-reports 354
- self-schema and self-worth 59–60
- serotonergic antidepressants, contraindications to MAOIs 299
- serotonergic and noradrenaline reuptake inhibitors (SNRIs) 295
- serotonergic system 94–5
  - antidepressant interactions 307–8
  - autoreceptors 307
- serotonin
  - conversion to melatonin 249–50
  - inactivation 307
  - peripheral marker 253–4
  - receptor subtypes 238
  - synthesis 306–7
- serotonin-selective reuptake inhibitors (SSRIs) 295
  - dosages **310**
  - drug interactions 310–11, **312**
  - effectiveness 96–7, **308**, 309–10
  - effects on cytochromes **312**
  - half-lives **311**
  - inhibition of cytochrome P450 isoenzymes **311**
  - risk–benefit ratio 310
  - see also* fluoxetine
- serotonin-specific drugs 306–11
- sertraline
  - dosage **310**
  - half-life **311**
- sertroline, effectiveness 309
- sex hormones, levels, and depression risk 221–2
- sexual abuse 212
  - correlated with suicidal behaviour 272–4
- shame 32
- sleep
  - cholinergic system, REM response 253
  - melatonin effects 250
- sleep patterns, dysregulation 92–4
- social competence, developmental precursors of depression 63–5
- social disadvantage 215–16
- social emotions 31–4
- social environment
  - developmental precursors of depression 46–68
  - measurement 207–11
- social factors, peer relationships 63–5
- social impairment, continuity/recurrence of depressive disorders 355–6
- social and nonsocial life events factors, major depressive disorder 219–22
- sociocentric source (of emotional intelligence) 26
- solipsistic source (of emotional intelligence) 26
- somatostatin (growth hormone-releasing hormone) 235–6, 238
- somatotropic axis,
  - hypothalamic–pituitary–somatotrophic axis 90, 95
- special needs 343–4
- Standard Psychiatric Interview 134
- stress levels, and life events 99–100
- substance use, and suicidal behaviour 281–3
- suicidal behaviour
  - comorbidity 281–4
  - conceptual framework **283**
  - and continuity of affective disorders 356–8
  - correlates 270–4
  - overdose, suicide completion 293
  - prevention strategies 283–4
  - psychology 275–81
  - cognitive repertoire 276

388 Index

suicidal behaviour (*cont.*)  
    hopelessness 279–80  
    impulsivity 277–8  
    risk factors 357–8  
suicidal ideation 270  
    defined 268  
    TSH blunting 241  
suicide 267–85  
    defined 268  
    epidemiology 268–70  
        correlates 269–70  
    historical aspects 15–16  
    media influences 279  
    psychological autopsy 358  
    TCA overdose 293  
superego phenomenon 13  
suprachiasmatic nucleus (SCN) 249  
synaptic transmission, drug interactions **308**  
syndrome(s)  
    defined 124–5  
    depression 128  
systemic behaviour family therapy (SBFT) 331–2  
  
temperament 53–5  
thymergastic reactions 13  
thyroid hormone 238–42  
    basal secretion 239–40  
    stimulated secretion 240–2  
thyroid-stimulating hormone (TSH),  
    hypothalamic–pituitary–thyroid axis 90–1  
tranylcypromine 296–7, 298  
    follow-up duration 333–4  
treatment regimes  
    cognitive behaviour therapy (CBT) 329–34, 335, 337  
    contextual psychotherapy (CP) 338  
    Coping with Depression (CWD) course 329–30, 336, 339  
    drug therapy 96  
    duration 340  
    efficacy 342  
    electroconvulsive therapy (ECT) 239  
    historical aspects 17  
    identifying those in need of treatment, optimal settings 339–40  
    interpersonal therapy (IPT) 332, 337  
    major depressive disorder 292–317  
    multifaceted, principal component analysis (PCA) 126, 126–7, 134–5, 343  
    nondiagnosed depressed/at-risk samples 334–7  
    nondirective supportive therapy (NST) 331–2  
  
outcome studies 328–37  
    comorbidity effects 333  
    paucity of outcome data 338–9  
parental role 341–2  
pharmacotherapy 292–317  
populations with special needs 343–4  
Primary and Secondary Control Enhancement Training (PASCET) 336  
psychosocial treatments 337–40  
psychotherapy, clinically diagnosed samples 329–34  
recommendations 316–17  
relaxation training (RT) 331, 335  
self-modelling 335  
supportive therapy vs. social skills therapy 330  
systemic behaviour family therapy (SBFT) 331–2  
tricyclic antidepressants  
    age groups **301**  
    contraindications 316  
    dosage regimens and plasma level monitoring 301–4, **303**  
    drug interactions **307**  
    evaluation 299–301  
    indications 306, 314–15  
    metaanalysis data **300**  
    nonresponse in children and adolescents 301  
    overdose, suicide completion 293  
    side-effects 304–6  
    *see also* amitriptyline; clomipramine; imipramine; lofepramine  
  
unipolar disorders 143–6  
    adult relatives of juvenile probands **193**  
    age and gender in diagnosis 148  
    genetic epidemiology 162–3  
    rates, from community studies **144–5**  
    *see also* dysthymia; major depression  
  
valproate, bipolar disorders 313  
vasoactive intestinal peptide (VIP) 239  
venlafaxine **311**  
Virginia Twin Study of Adolescent Behavioral Development 162  
vulnerability to depression, developmental model 67–8  
  
weight changes, atypical depression 100  
  
X-linked inheritance, bipolar disorders 197  
  
Yale Family Study 183